These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36735195)

  • 1. Challenges in Implementing Futility Schemes, with Reference to Aducanumab.
    Gallo P; Roychoudhury S
    Ther Innov Regul Sci; 2023 May; 57(3):515-520. PubMed ID: 36735195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic survey of randomised trials that stopped early for reasons of futility.
    Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
    BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal futility stopping boundaries for binary endpoints.
    Freitag MM; Li X; Rauch G
    BMC Med Res Methodol; 2024 Mar; 24(1):80. PubMed ID: 38539108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A flexible futility monitoring method with time-varying conditional power boundary.
    Ying Zhang ; Clarke WR
    Clin Trials; 2010 Jun; 7(3):209-18. PubMed ID: 20423927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative views on setting clinical trial futility criteria.
    Gallo P; Mao L; Shih VH
    J Biopharm Stat; 2014; 24(5):976-93. PubMed ID: 24933121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upstrapping to determine futility: predicting future outcomes nonparametrically from past data.
    Wild JL; Ginde AA; Lindsell CJ; Kaizer AM
    Trials; 2024 May; 25(1):312. PubMed ID: 38725072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of futility monitoring guidelines using completed phase III oncology trials.
    Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
    Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
    Walter SD; Han H; Briel M; Guyatt GH
    Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
    Li X; Herrmann C; Rauch G
    BMC Med Res Methodol; 2020 Nov; 20(1):274. PubMed ID: 33153438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.
    Yi J; Fang L; Su Z
    Contemp Clin Trials; 2012 Jan; 33(1):138-42. PubMed ID: 21983624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of combining two independent trials in interim futility analysis.
    Deng Q; Zhang YY; Roy D; Chen MH
    Stat Methods Med Res; 2020 Feb; 29(2):522-540. PubMed ID: 30957713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience.
    Yeatts SD; Martin RH; Coffey CS; Lyden PD; Foster LD; Woolson RF; Broderick JP; Di Tullio MR; Jungreis CA; Palesch YY;
    Stroke; 2014 May; 45(5):1408-14. PubMed ID: 24699059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.
    Lesaffre E; Edelman MJ; Hanna NH; Park K; Thatcher N; Willemsen S; Gaschler-Markefski B; Kaiser R; Manegold C
    Ann Oncol; 2017 Jul; 28(7):1419-1426. PubMed ID: 28184431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of futility boundaries for group sequential designs with two endpoints.
    Schüler S; Kieser M; Rauch G
    BMC Med Res Methodol; 2017 Aug; 17(1):119. PubMed ID: 28789615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution.
    Waleed M; He J; Phadnis MA
    Pharm Stat; 2021 May; 20(3):610-644. PubMed ID: 33565236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.